NuGenerex Immuno-Oncology, Inc. (NUGX) Stock Analysis
DELISTED
What happened to NuGenerex Immuno-Oncology, Inc. (NUGX) stock?
NuGenerex Immuno-Oncology, Inc. (NUGX) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
NuGenerex Immuno-Oncology, Inc. (NUGX). NuGenerex Immuno-Oncology, Inc. is a biotechnology company focused on developing immunotherapeutic products and vaccines for cancer treatment. Their lead product, AE37, is currently in Phase II clinical trials for metastatic triple-negative breast cancer.
Last analyzed: Mar 17, 2026NuGenerex Immuno-Oncology, Inc. (NUGX) Healthcare & Pipeline Overview
NUGX OTC Market Information
NUGX trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
More about this archive record
Can I still buy NUGX shares?
No. NUGX stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for NUGX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before NUGX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to NuGenerex Immuno-Oncology, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.